Option chain shows key data for OneMedNet's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for OneMedNet.

OneMedNet (NASDAQ:ONMD) Stock, Option Chain

OneMedNet

OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data or iRWDTM. OneMedNet's innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct access to clinical images and the associated contextual patient record.

movers image

News

Intraday Update

Markets

Movers

Trading Ideas

ADBE

BAND

BIMI

CABA

CANF

CNSP

CORT

FOXO

GANX

INAB

IONM

IRON

JFBR

KAVL

KITT

KYTX

LGVN

NAAS

NNVC

NVAX

OCUL

ONMD

PENN

POWW

RARE

RNXT

RZLT

SVMH

THMO

TWOU

WLFC

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Digital,Marketing,Data,Analytic,Technology,,Businessman,Using,Laptop,Computer,To

Exclusives

$BTC

AAPL

AMZN

ASTS

COIN

CTNT

DELL

FFIE

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LIDR

NVDA

PLTR

SMCI

TSLA

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In May: Where Do Nvidia, Tesla, GameStop, AMC Rank?

xr:d:DAFlJKNXbrw:2,j:4527636209394207909,t:23060712

AEMD

AIRJ

AONC

ASNS

ASST

BASE

BNRG

CHSN

CLEU

CODX

FDMT

FIVE

FRES

FRGT

GIII

HALO

ISPC

JWEL

LIVN

LULU

MITQ

MSGM

NDRA

OLLI

PHAR

PLTN

PXDT

REPL

RYDE

SCWX

SMAR

SNBR

TRSG

UNFI

VIRI

VNDA

VRAX

VTYX

XPOF

ZCAR

Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

OneMedNet Corp

OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) ("OneMedNet" or the "Company"), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data ("iRWD&#x2122;"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(b)(2) (the "Rule") after the market value of the Company's common stock exceeded $35,000,000 for 10 consecutive business days. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") confirming compliance with the Rule.&nbsp;&nbsp; As a result, the Company has cleared all listing deficiency notices issued by Nasdaq.
Aaron Green, Chief Executive Officer, stated, "We are pleased to have now achieved compliance with the Nasdaq listing rules. This accomplishment will enable us to focus in 2025 on growing our revenue and business operations."
During the 2024 and 2025, we developed and started to execute on our strategic plan by:
<ul>
<li>Expanding its product offerings, which now include data masking solutions for additional industries and subscription-based offerings for the Company's healthcare and real-world data solutions.</li>
<li>Appointing Bob Golden as Chief Financial Officer to oversee enhancements in the Company's financial reporting processes.</li>
<li>Hiring a Director of Business Development, Margaret Nash, and Vice President of Marketing, Michael Wong, to continue to build our commercial presence with Life Science organizations, additionally recently signing an agreement with Bayer's AI Innovation Platform (AIIP) announced in early December 2024.</li>
<li>Enhancing our Data De-Identification and curation service leveraging Generative AI and deploying OneMedNet's 2.0 generation indexer OMNi, to improve the speed and accuracy of data searching and indexing.</li>
<li>Refreshing the composition of the Company's Board of Directors with three new directors who have relevant industry, financial and public company expertise.</li>
<li>Improving liquidity by raising approximately $6.4M in private placements with Off the Chain Capital and an affiliate of Discovery Capital Management.</li>
<li>Enhancing treasury management with a Bitcoin on the balance sheet strategy.</li>
</ul>
OneMedNet is now in a position to take advantage of the growing Real World Data market with a meaningful market share.

OneMedNet Regains Compliance With NASDAQ Listing Requirements

OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) ("OneMedNet" or the "Company"), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data ("iRWD&#x2122;"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(a)(2) (the "Rule") after the closing bid price of the Company's common stock was $1.00 per share or greater for 10 consecutive business days. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") confirming compliance with the Rule.

OneMedNet Regains Compliance With NASDAQ Minimum Bid Price Requirements

OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) (&quot;OneMedNet&quot; or the &quot;Company&quot;), a Real-World Data (RWD) platform &mdash; has announced its collaboration with Bayer&#39;s AI Innovation Platform (AIIP). By joining AIIP, the partnership aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products.

Biotech

General

OneMedNet Announces New Collaboration With Bayer's AI Innovation Platform To Help Developers Have Access To Comprehensive Tools And The Precise Datasets Necessary For Creating Effective And Compliant AI Healthcare Applications

OneMedNet Reveals Receipt Of Nasdaq Notice About Non-Compliance Regarding Delayed Form 10-Q

<h3>Gainers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock rose 213.0% to $0.92 during Monday's pre-market session. The market value of their outstanding shares is at $34.8 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) shares increased by 91.65% to $0.18. The market value of their outstanding shares is at $20.1 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock moved upwards by 33.02% to $0.87. The company's market cap stands at $8.7 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares moved upwards by 29.9% to $2.65. The company's market cap stands at $1.9 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) shares rose 20.84% to $44.58. The company's market cap stands at $2.6 billion. The company's, Q4 earnings came out today. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) shares moved upwards by 20.24% to $6.0. The market value of their outstanding shares is at $18.2 million. As per the press release, Q3 earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares declined by 41.2% to $0.99 during Monday's pre-market session. The company's market cap stands at $3.7 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock declined by 36.55% to $21.9. The market value of their outstanding shares is at $324.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares decreased by 17.45% to $2.13. The company's market cap stands at $5.3 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock fell 14.38% to $0.71. The company's market cap stands at $3.8 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares fell 11.69% to $0.77. The company's market cap stands at $21.7 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock fell 10.28% to $0.55. The market value of their outstanding shares is at $2.6 million. The company's, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLM

CMAX

CYCN

ERNA

HCWB

NGNE

NIVF

SINT

TRAW

TWST

VRPX

12 Health Care Stocks Moving In Monday's Pre-Market Session

WIIM

OneMedNet shares are trading higher after it announced continued investment in Bitcoin which is currently seeing record highs.

OneMedNet shares are trading higher after the company announced an additional strategic investment in Bitcoin.

OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) ("OneMedNet" or the "Company"), a pioneer in curating regulatory-grade Real World Data (RWD) including electronic health records, laboratory results, and medical imaging, has announced an additional strategic investment in Bitcoin. This investment is designed to enhance the company's financial resilience and support the expansion of its cutting-edge iRWD&#x2122; platform. As of November 12, 2024, the Company has invested in approximately 34 Bitcoin.
Off The Chain Capital has made significant investments in OneMedNet through multiple funding rounds, and their expertise regarding Bitcoin has been invaluable. Brian Estes, Chief Investment Officer, of Off The Chain Capital, shared, "We believe Bitcoin will become the monetary layer of the world over the next few decades, much like gold was for over 3000 years. Companies that embrace this vision will gain a strategic advantage over those losing the purchasing power of their treasury reserves due to the debasement of fiat currencies."
OneMedNet has adopted a Bitcoin on the balance sheet strategy based on the approach Michael Saylor and MicroStrategy (MSTR) pioneered, which reflects a forward-looking approach to corporate treasury management that incorporates digital currencies.
This investment is part of OneMedNet's commitment to sustainable growth and innovation that supports the healthcare community through high-quality, compliant regulatory grade clinical data. The iRWD&#x2122; platform provides secure, comprehensive management of diverse de-identified clinical data, from electronic health records and laboratory results to medical imaging, across our network of 1,400+ healthcare partner sites playing a crucial role in advancing medical research, improving patient care, and driving healthcare innovation.

OneMedNet Announces As Of November 12, 2024, The Company Has Invested In ~ 34 Bitcoin

<h3>Gainers</h3>
<ul>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares increased by 66.0% to $4.4 during Friday's pre-market session. The company's market cap stands at $86.8 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock rose 43.83% to $2.1. The market value of their outstanding shares is at $2.8 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares rose 26.13% to $0.54. The market value of their outstanding shares is at $20.6 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 18.06% to $36.62. The company's market cap stands at $122.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares rose 16.79% to $6.26. The market value of their outstanding shares is at $230.5 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock moved upwards by 16.04% to $4.05. The market value of their outstanding shares is at $307.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares fell 39.5% to $1.18 during Friday's pre-market session. The market value of their outstanding shares is at $426.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock declined by 10.37% to $0.77. The company's market cap stands at $18.3 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 9.76% to $1.11. The company's market cap stands at $6.1 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock declined by 9.1% to $1.6. The company's market cap stands at $15.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 9.1% to $1.3. The market value of their outstanding shares is at $20.1 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares decreased by 8.07% to $0.57. The market value of their outstanding shares is at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATHA

BFRI

BIAF

CDXC

Envoy Medical, Inc. - Class A Common Stock

COCH

LXRX

MOLN

MTNB

PDEX

TOVX

TRIB

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock moved upwards by 66.0% to $4.4 during Friday's pre-market session. The market value of their outstanding shares is at $86.8 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 43.83% to $2.1. The company's market cap stands at $2.8 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock increased by 26.13% to $0.54. The company's market cap stands at $20.6 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 18.06% to $36.62. The market value of their outstanding shares is at $122.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 16.79% to $6.26. The company's market cap stands at $230.5 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 16.04% to $4.05. The company's market cap stands at $307.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) stock decreased by 39.5% to $1.18 during Friday's pre-market session. The market value of their outstanding shares is at $426.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 10.37% to $0.77. The market value of their outstanding shares is at $18.3 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares declined by 9.76% to $1.11. The market value of their outstanding shares is at $6.1 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares fell 9.1% to $1.6. The company's market cap stands at $15.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 9.1% to $1.3. The market value of their outstanding shares is at $20.1 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock declined by 8.07% to $0.57. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

<h3>Gainers</h3>
<ul>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares rose 48.3% to $0.53 during Thursday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) stock moved upwards by 32.92% to $1.45. The company's market cap stands at $370.9 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares rose 9.64% to $1.25. The market value of their outstanding shares is at $41.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 8.74% to $0.87. The company's market cap stands at $20.7 million. </li>
<li>Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) shares increased by 7.32% to $75.5. The market value of their outstanding shares is at $45.4 billion. As per the press release, Q3 earnings came out today. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 6.85% to $1.87. The market value of their outstanding shares is at $21.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) stock declined by 15.2% to $63.5 during Thursday's after-market session. The company's market cap stands at $25.4 billion. The company's, Q3 earnings came out today. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) stock declined by 14.29% to $1.02. The market value of their outstanding shares is at $44.1 million. </li>
<li>Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) shares declined by 10.98% to $200.0. The company's market cap stands at $13.3 billion. As per the press release, Q3 earnings came out today. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock decreased by 6.65% to $1.11. The market value of their outstanding shares is at $98.7 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 6.34% to $0.82. The market value of their outstanding shares is at $2.2 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) shares fell 5.55% to $0.71. The market value of their outstanding shares is at $2.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

BNOX

DXCM

LYEL

QNCX

RVPH

SCPX

VTAK

12 Health Care Stocks Moving In Thursday's After-Market Session

OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Real World Data ("RWD"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that it has entered into a securities purchase agreement with an affiliate of Off the Chain Capital (collectively, "Off the Chain") in a follow-on private placement that resulted in gross proceeds of approximately $1.7 million, before deducting fees and expenses payable by the Company. OneMedNet previously consummated a private placement with Off the Chain Capital on July 24, 2024 that resulted in gross proceeds of $2.7 million. &nbsp;
The private placement closed on September 25, 2024. The price per share of common stock sold in this offering meets the minimum price requirement under Nasdaq rules. The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes. Pending use of the funds, the Company plans to use a portion of the net proceeds to purchase Bitcoin ($BTC).
Pursuant to the terms of the securities purchase agreement, OneMedNet sold an aggregate of 1,918,591 shares of its common stock at a price of $0.65 per share, warrants exercisable for 133,095 shares of its common stock at an exercise price of $0.325 per share and pre-funded warrants exercisable for 743,314 shares of its common stock at an exercise price of $0.65 per share. The investor prepaid the exercise price for the pre-funded warrants, other than $0.0001 per share. The terms of the transaction were otherwise generally consistent with the previous Off the Chain private placement.

Offerings

OneMedNet Announces Additional $1.7M Private Placement, Before Deducting Fees And Expenses Payable By The Company; OneMedNet Sold An Aggregate Of 1,918,591 Shares Of Its Common Stock At A Price Of $0.65 Per Share

OneMedNet Receives Notice From Nasdaq Listing Qualifications Department Regarding Delayed Forms 10-Q

Management

OneMedNet Appoints Bob Golden As CFO

OneMedNet shares are trading higher after the company announced a $4.6M private placement.

OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Real World Data ("RWD"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that it has entered into securities purchase agreements with certain institutional investors, including an affiliate of Off the Chain Capital and an affiliate of Discovery Capital Management, in a private placement that resulted in gross proceeds of approximately $4.6 million, before deducting fees and expenses payable by the Company. The private placement closed on July 25, 2024. The price per share of common stock sold in this offering meets the minimum price requirement under Nasdaq rules. The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes. Pending use of the funds, the Company used $1.8 million of the net proceeds to purchase Bitcoin ($BTC). &nbsp;
Pursuant to the terms of the securities purchase agreement with an affiliate of Off the Chain Capital, OneMedNet sold an aggregate of 1,297,059 shares of its common stock at a price of $1.0278 per share and pre-funded warrants exercisable for 1,323,530 shares of its common stock at an exercise price of $1.0278 per share. The investor prepaid the exercise price for the pre-funded warrants, other than $0.0001 per share.
Pursuant to the terms of the securities purchase agreement with an affiliate of Discovery Capital Management, OneMedNet sold an aggregate of 2,301,791 shares of its common stock at a price of $0.85 per share.

Financing

OneMedNet Announces $4.6M Private Placement

OneMedNet Says Cytel Has Identified Itself As The Other Party With Which OneMedNet Recently Entered An iRWD Customer Data License

- Regains compliance with Nasdaq minimum closing bid price rule&nbsp;- &nbsp;
- Secures financing from institutional investor to support aggressive growth plans -
MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Real World Data ("RWD"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today provided a number of corporate updates.

OneMedNet Announces Related Receipt Of Nasdaq Notice Regarding Delayed Form 10-Q, Has Regained Compliance With Nasdaq Minimum Closing Bid Price Rule

Shares of AMMO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) fell sharply during Friday's session <a href="https://www.benzinga.com/quote/POWW/earnings">following fourth-quarter results</a>.
AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for a loss of 1 cent per share. The company reported quarterly sales of $40.42 million topping estimates of $37.90 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
AMMO shares dipped 19.1% to $2.0306 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Kaival Brands Innovations Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) shares jumped 345% to $6.06.</li>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) gained 150% to $0.3852 after the company announced it will begin accepting paid reservations and bookings for its flagship product, the PRANA 2.0, on June 16th.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) surged 42.5% to $5.16.</li>
<li>FOXO Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NASDAQ">FOXO</a>) shares gained 29% to $0.3092 after the company announced it entered into share exchange agreements with Rennova Health.</li>
<li>Jeffs&#8217; Brands Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) surged 29% to $0.4528.</li>
<li>BIMI Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) gained 25.7% to $2.15.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) rose 23.4% to $3.36.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) gained 20% to $1.4599 as the company announced iRWD customer data license agreement with a leading U.S.-based global clinical trial design and software company.</li>
<li>Can-Fite BioPharma Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANF#NYSE">CANF</a>) jumped 17.9% to $4.28.</li>
<li>Disc Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) rose 15.6% to $45.29. Disc Medicine announced a $178 million underwritten offering of 4.944 million shares at $36 per share.</li>
<li>Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) rose gained 14.3% to $524.39 following better-than-expected second-quarter earnings and strong guidance.</li>
<li>RenovoRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) surged 14.3% to $1.2001.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) gained 14.1% to $5.75 as the company highlighted AXPAXLI SOL-1 enrollment and plans repeat dosing study in wet AMD.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 14% to $0.1836 after dipping 17% on Thursday.</li>
<li>VinFast Auto Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) gained 9.9% to $4.32. VinFast Auto anticipates sustained growth for next five years and approaching break-even point.</li>
<li>Tutor Perini Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) rose 9.9% to $21.11. UBS analyst Steven Fisher upgraded Tutor Perini from Neutral to Buy and raised the price target from $14 to $27.</li>
<li>Willis Lease Finance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLFC#NASDAQ">WLFC</a>) gained 6.4% to $64.99.</li>
<li>Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) gained 5.5% to $61.22 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $70 to $80.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares dipped 43.3% to $116.47 after announcing a $3.5 billion private placement.</li>
<li>Nexalin Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares fell 33.3% to $0.9192 after jumping 121% on Thursday. Nexalin Technology recently announced regulatory approval of Gen-2 15mA neurostimulation device by Brazilian Health Regulatory Agency.</li>
<li>IN8bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) dipped 31.1% to $1.1598 after the company presented data from its Phase 1 trial of INB-100 showing 100% of treated leukemia patients achieved durable complete remission at 1 year.</li>
<li>Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) fell 28.1% to $1.3599 after the company announced the pricing of a $11 million public offering of 7,116,547 shares at $1.35 per share and pre-funded warrants.</li>
<li>Kyverna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) dipped 24.8% to $10.88.</li>
<li>Rezolute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) shares fell 24.3% to $3.90 after the company announced pricing of public offering of $60 million of common stock and pre-funded warrants.</li>
<li>ThermoGenesis Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) dipped 20.2% to $0.3302.</li>
<li>NaaS Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) fell 20.2% to $5.66. The company announced completion of ADS ratio change.</li>
<li>NanoViricides, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NASDAQ">NNVC</a>) fell 19.3% to $2.08</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) shares fell 19.2% to $0.7141 after jumping over 35% on Thursday.</li>
<li>Ostin Technology Group Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) fell 19.2% to $0.4020 after jumping 24% on Thursday.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares fell 18.6% to $225.60 after the company reported mixed first-quarter financial results.</li>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) declined 15.3% to $0.26.</li>
<li>Bandwidth Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAND#NASDAQ">BAND</a>) fell 13.1% to $16.07. Morgan Stanley analyst Meta Marshall downgraded Bandwidth from Equal-Weight to Underweight and lowered the price target from $18 to $15.</li>
<li>Cabaletta Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) dipped 12.5% to $10.99 as the company announced initial clinical data from Phase 1/2 RESET-Myositis and RESET-SLE trials of CABA-201.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) fell 10.5% to $6.11.</li>
<li>Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) dipped 10% to $28.36.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) fell 9.7% to $13.59.</li>
<li>PENN Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) fell 9.6% to $17.23. Truist Securities analyst Barry Jonas maintained PENN Entertainment with a Buy and raised the price target from $23 to $25.</li>
<li>ATI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) fell 9.6% to $51.65.</li>
<li>MSC Industrial Direct Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) shares declined 8.3% to $77.48 after the company reported preliminary third-quarter financial results below estimates and cut its FY24 adjusted operating margin.</li>
<li>Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) fell 7.7% to $39.82 as the company announced the pricing of public offering of common stock and pre-funded warrants.</li>
<li>WESCO International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) fell 7.1% to $161.79.</li>
<li>Carnival plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUK#NYSE">CUK</a>) fell 6.7% to $13.89.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) fell 5.7% to $14.23.</li>
<li>Telephone and Data Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) fell 5.6% to $18.93</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39331763/dell-palo-alto-networks-and-2-other-stocks-insiders-are-selling">Dell, Palo Alto Networks And 2 Other Stocks Insiders Are Selling</a>

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session

OneMedNet Announces iRWD Customer Data License Agreement With Leading U.S.-Based Global Clinical Trial Design And Software Company; Provides Regulatory-Grade Real World Data Including EHRs, Lab Results, And Medical Imaging

OneMedNet raises $1.7M through additional private placement

OneMedNet ( ($ONMD) ) just unveiled an update. OneMedNet Corporation has secured $1.7 million in a private placement deal with an institutional inv...

OneMedNet: New Funding, Bitcoin Investment, and Equity Sales

OneMedNet (ONMD) has announced an additional strategic investment in Bitcoin ($BTC). This investment is designed to enhance the company's financial...

OneMedNet announces continued investment in bitcoin

OneMedNet announces non-compliance notice from Nasdaq

OneMedNet Corporation (ONMD) announced its collaboration with Bayer's (BAYRY) AI Innovation Platform. By joining AIIP, the partnership aims to empo...

OneMedNet announces collaboration with Bayer's AI Innovation Platform

OneMedNet regains Nasdaq compliance

OneMedNet (ONMD) regained compliance with Nasdaq Listing Rule 5250(c)(1) based on the filing of its periodic reports on Form 10-Q for the fiscal qu...

OneMedNet regains compliance with Nasdaq filing requirements

OneMedNet ( ($ONMD) ) has issued an announcement. OneMedNet Corporation has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing it...

OneMedNet Regains Nasdaq Compliance and Eyes Growth

OneMedNet Corporation regains Nasdaq compliance

OneMedNet regains compliance with Nasdaq

BAYRY

BAYZF

Press Releases

OneMedNet appoints new CFO

OneMedNet Announces Receipt of Nasdaq Notices Regarding Delayed Forms 10-Q

OneMedNet Announces Additional $1.7 Million Private Placement

OneMedNet Announces Board Member Transition to Drive Growth Post-IPO

OneMedNet Announces Continued Investment into Bitcoin

OneMedNet Announces Receipt of Nasdaq Notice Regarding Delayed Form 10-Q

OneMedNet Announces Exciting New Collaboration with Bayer's AI Innovation Platform to Help Accelerate Healthcare AI Development

OneMedNet Regains Compliance with NASDAQ Periodic Filing Requirements

OneMedNet Regains Compliance with NASDAQ Minimum Bid Price Requirements

OneMedNet Regains Compliance with NASDAQ Listing Requirements

TALN

Comments

OneMedNet

OneMedNet (ONMD) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga